Rimeporide is an investigational small molecule, categorized as a 2-amino-4,5-bis(methylsulfonyl)benzamide derivative, currently being evaluated in clinical research for the treatment of Duchenne muscular… Read more
Rimeporide is an investigational small molecule, categorized as a 2-amino-4,5-bis(methylsulfonyl)benzamide derivative, currently being evaluated in clinical research for the treatment of Duchenne muscular dystrophy and other neuromuscular disorders. By inhibiting eukaryotic initiation factor 2 (eIF2A), this compound modulates protein synthesis, and as it progresses through development, pharmaceutical laboratories require high-quality reference standards for rigorous analytical testing and method validation. This category provides access to Rimeporide and its related compounds, including stable isotope labelled derivatives like Rimeporide-15N3 Hydrochloride. These specialized compounds are essential tools for accurate impurity profiling and precise quantification of the parent drug and its metabolites during pharmacokinetic studies and routine quality control analysis. Utilizing such characterized reference materials ensures consistency and reliability in experimental workflows, supporting the broader development of this therapeutic candidate.